First Japanese company joins CARB-X partnership
Custom Synthesis, CARB-X is partnering with Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity against the dreaded superbug serine- and metallo-type carbapenemase-producers, including BL/BLI-resistant carbapenem-resistant Enterobacteriaceae (CRE).
Under the agreement, Shionogi will receive an initial award of up to $4.7M, with the possibility of $2.9M more from CARB-X based on the achievement of certain project milestones.
“We are very excited to welcome the first Japanese company into the Powered by CARB-X portfolio, strengthening the global fight against drug-resistant bacteria. Shionogi’s commitment to antibacterial innovation and its reputation for research excellence bodes well for this new collaboration,” said Kevin Outterson, Executive Director of CARB-X. “The world urgently needs innovative approaches, like the Shionogi project, to protect us from drug-resistant bacteria. The projects in the CARB-X portfolio are in the early stages of research, and there is always a risk of failure. But if successful, they hold great potential to treat serious infections and to save lives.”http://www.haihengpharma.com/first-japanese-company-joins-carb-x-partnership/News